

PATIENT	AGE (YEARS)	RACE	BASELINE ECOG	PREVIOUS LINES OF THERAPY	CASTRATION STATUS	METASTASES	BASELINE PSA (NG/ML)	PSA NADIR (NG/ML)	TIME TO DISEASE PROGRESSION	ADVERSE EFFECTS	TREATMENT OUTCOME
1	87	White	1	Brachytherapy	Sensitive	Bone	913.11	0.63		Hypokalemia, Hypertension, Edema	Continues on treatment after switching to dexamethasone
2	67	White	1		Sensitive	Bone	218.1	0.36		Hypertension	Continues on treatment
3	70	White	0	Bicalutamide Docetaxel Carboplatin+Paclitaxel Carboplatin+Fluorouracil	Resistant	Bone, Lung	133.28	21.84	115 days	Hypertension	Switched to dexamethasone but is pending switch to enzalutamide after noted abiraterone resistance
4	67	White	0		Sensitive	Bone	3.99	0.03		Elevated ALT/AST, Hypertension	Discontinued and switched to enzalutamide due to hepatotoxicity
5	70	White	0	Radiation Bicalutamide	Sensitive	Bone, Lung	5.01	0.08		Hypokalemia, Elevated ALT/AST	Continues on treatment after switching to dexamethasone
6	80	White	1	Radiation Bicalutamide Brachytherapy	Sensitive	Bone, Lung	11.8	0.07		Hypokalemia, Hypertension	Continues on treatment
7	76	Asian	0	Bicalutamide	Resistant	Bone	4.89	0.18	428 days	Hypertension, Edema	Continues on treatment after switching to dexamethasone
8	85	White	0	Bicalutamide	Sensitive	Bone	4076.26	1.44		Hypokalemia, Hypertension, Edema	Continues on treatment
9	68	White	1	Bicalutamide	Sensitive	Bone, Lung	478	1.84			Continues on treatment
10	70	White	3	Cabazitaxel Enzalutamide Radiation	Resistant	Bone, Liver, Lymph Node	175.57	135.03			Passed away due to severe comorbidities one month into treatment
11	73	White	1	Bicalutamide	Sensitive	Liver, Lymph Node	158.73	<0.03		Hypokalemia, Hypertension	Continues on treatment
12	87	White	1	Radiation Brachytherapy Bicalutamide	Resistant	Bone	7.46	1.32		Elevated ALT/AST, Hypertension	Continues on every-other-day treatment due to hepatotoxicity after switching to dexamethasone
13	87	White	1	Brachytherapy Bicalutamide	Resistant	Lymph Node	3.14	0.12		Hypertension	Continues on treatment